Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28861530 | 0.86 | CPB2 (0.45) | ALDH1A1GFERHTTNPSR1CPB2 | |
| SCHEMBL2084230 | 0.83 | ALDH1A1 (0.48) | ALDH1A1GFERHTTNPSR1NQO2 | |
| SCHEMBL13256665 | 0.82 | CPB2 (0.41) | ALDH1A1CPB2NQO2CPB1 | |
| SCHEMBL5450093 | 0.81 | ALDH1A1 (0.43) | ALDH1A1GFERHTTNPSR1NQO2 | |
| SCHEMBL1568982 | 0.81 | CPB2 (0.41) | ALDH1A1GFERHTTNPSR1CPB2 | |
| SCHEMBL21071078 | 0.81 | CA1 (0.46) | CPB2CPB1CA1CA2CA12 | |
| SCHEMBL4701416 | 0.80 | CPB2 (0.41) | CPB2CPB1 | |
| SCHEMBL13239683 | 0.80 | ALDH1A1 (0.38) | ALDH1A1HTTCPB2CPB1CA2 | |
| SCHEMBL21069415 | 0.79 | TDP1 (0.47) | ALDH1A1GFERNPSR1CPB2CA1 | |
| SCHEMBL2687010 | 0.76 | ALDH1A1 (0.40) | ALDH1A1GFERHTTNPSR1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2357179-A1 | Thiazol-2-yl organic compounds | Novartis AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | AKT3, PIK3R3, PIK3CD | ALDH1A1 3448/4885GFER 4549/4885HTT 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.